Abstract
Thyroid carcinoma is an uncommon malignancy in children, and metastatic involvement at initial presentation is much more common than adults. The clinical course of the disease is favorable; however, management is challenging due to differences in biologic behavior of the tumor and potential side effects of I-131 in the long-term follow-up. The current pediatric case highlights the possible pulmonary fibrosis after radioiodine treatment and indicates the importance of dose optimization particularly in children with diffuse lung metastases.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Francis GL, Waguespack SG, Bauer AJ, Angelos P, Benvenga S, Cerutti JM, et al. Management guidelines for children with thyroid nodules and differentiated thyroid Cancer. Thyroid. 2015;25:716–59. https://doi.org/10.1089/thy.2014.0460.
Luster M, Clarke SE, Dietlein M, Lassmann M, Lind P, Oyen WJ, et al. Guidelines for radioiodine therapy of differentiated thyroid cancer. Eur J Nucl Med Mol Imaging. 2008;35:1941–59. https://doi.org/10.1007/s00259-008-0883-1.
Luster M, Pfestroff A, Hänscheid H, Verburg FA. Radioiodine therapy. Semin Nucl Med. 2017;47:126–34. https://doi.org/10.1053/j.semnuclmed.2016.10.002.
Verburg FA, Van Santen HM, Luster M. Pediatric papillary thyroid cancer: current management challenges. Onco Targets Ther. 2016;28:165–75. https://doi.org/10.2147/OTT.S100512.
Albano D, Bertagna F, Panarotto MB, Giubbini R. Early and late adverse effects of radioiodine for pediatric differentiated thyroid cancer. Pediatr Blood Cancer. 2017;64:1–7. https://doi.org/10.1002/pbc.26595.
Samuel AM, Rajashekharrao B, Shah DH. Pulmonary metastases in children and adolescents with well-differentiated thyroid cancer. J Nucl Med. 1998;39:1531–6.
Hebestreit H, Biko J, Drozd V, Demidchik Y, Burkhardt A, Trusen A. Pulmonary fibrosis in youth treated with radioiodine for juvenile thyroid cancer and lung metastases after Chernobyl. Eur J Nucl Med Mol Imaging. 2011;38:1683–90. https://doi.org/10.1007/s00259-011-1841-x.
Benua RS, Leeper RD. A method and rationale for treating metastatic thyroid carcinoma with the largest safe dose of 131I. In: Mederios-Neta G, Gaitan E, editors. Frontiers in thyridology. New York: Plenum Medical; 1986. p. 1317–21.
Tsoutsou PG, Koukourakis MI. Radiation pneumonitis and fibrosis: mechanisms underlying its pathogenesis and implications for future research. Int J Radiat Oncol Biol Phys. 2006;66:1281–93.
Giridhar P, Mallick S, Rath GK, Julka PK. Radiation induced lung injury: prediction, assessment and management. Asian Pac J Cancer Prev. 2015;16(7):2613.
Song H, He B, Prideaux A, Du Y, Frey E, Kasecamp W, Ladenson PW, et al. Lung dosimetry for radioiodine treatment planning in the case of diffuse lung metastases. J Nucl Med. 2006;47:1985–94.
Verburg FA, Biko J, Diessl S, Demidchik Y, Drozd V, Rivkees SA, et al. I-131 activities as high as safely administrable (AHASA) for the treatment of children and adolescents with advanced differentiated thyroid cancer. J Clin Endocrinol Metab. 2011;96:E1268–71. https://doi.org/10.1210/jc.2011-0520.
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2019 Springer International Publishing AG, part of Springer Nature
About this chapter
Cite this chapter
Özcan, Z., Yararbaş, Ü. (2019). Pediatric PTC with Diffuse Lung Metastases: Pulmonary Function Testing and Steroid Therapy Prior to RAI. In: Özülker, T., Adaş, M., Günay, S. (eds) Thyroid and Parathyroid Diseases. Springer, Cham. https://doi.org/10.1007/978-3-319-78476-2_67
Download citation
DOI: https://doi.org/10.1007/978-3-319-78476-2_67
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-78475-5
Online ISBN: 978-3-319-78476-2
eBook Packages: MedicineMedicine (R0)